HRTX
HERON THERAPEUTICS, INC. /DE/
NASDAQ · Healthcare · Biotechnology · US
$0.31
−1.90%Aug 10, 2026, 00:00 UTC
Heron Therapeutics reported Q2 2026 total net revenue of $37.7 million, up 1.3% year-over-year, with a net loss of $5.5 million and diluted EPS of -$0.03.
Jun 2, 2026, 12:12 UTC
The U.S. District Court for the District of Delaware issued a decision in patent litigation between Heron Therapeutics and Azurity Pharmaceuticals, holding Heron's asserted patents for CINVANTI invalid.
Source: